drugset / Trial / NCT01161914

The Safety and Efficacy Study of ISU302 in Patient With Type I Gaucher Disease

NCT01161914

Phase 3 Withdrawn ISU Abxis Co., Ltd.
RandomizedParallel-groupDouble-blind

Summary

The purpose of this study is to compare and evaluate the efficacy and safety of ISU302, an investigational product, and Cerezyme®, comparator, for Type 1 Gaucher Disease patients

Timeline

Start
2011-01
Primary completion
2011-08
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject ISU302 Protein / enzyme biologic 60 iu/kg Intravenous
Comparator Imiglucerase Protein / enzyme biologic 60 iu/kg Intravenous